8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Feb 10, 2026·SEC
Zimmer Biomet Holdings, Inc.(ZBH)Earnings, Financials & Key Ratios
ZBH•NYSE
24.8× P/E·Price updated Jun 19, 2026
AboutZimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.Show more
- Revenue$8.23B+7.2%
- EBITDA$2.46B+7.6%
- Net Income$705M-22.0%
- EPS (Diluted)3.55-19.9%
- Gross Margin61.62%-13.8%
- EBITDA Margin29.84%+0.4%
- Operating Margin16.55%-1.2%
- Net Margin8.57%-27.2%
- ROE5.6%-22.7%
ZBH Key Insights
Zimmer Biomet Holdings, Inc. (ZBH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 17.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 2.6% through buybacks
- ✓Trading at only 1.4x book value
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZBH Price & Volume
Zimmer Biomet Holdings, Inc. (ZBH) stock price & volume — 10-year historical chart
Loading chart...
ZBH Growth Metrics
Zimmer Biomet Holdings, Inc. (ZBH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.22%
5 Years6.08%
3 Years5.85%
TTM9.23%
Profit CAGR
10 Years16.98%
5 Years-
3 Years44.98%
TTM-16.65%
EPS CAGR
10 Years29.87%
5 Years-
3 Years47.78%
TTM-14.82%
Return on Capital
10 Years4.08%
5 Years5.66%
3 Years6.87%
Last Year6.91%
ZBH Recent Earnings
Zimmer Biomet Holdings, Inc. (ZBH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$2.09+12.4%
$1.86
Rev
$2.1B+0.8%
$2.1B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$2.42+1.7%
$2.38
Rev
$2.2B+0.9%
$2.2B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.90+1.6%
$1.87
Rev
$2.0B-0.5%
$2.0B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.07+4.5%
$1.98
Rev
$2.1B+1.0%
$2.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $2.09vs $1.86+12.4% | $2.1Bvs $2.1B+0.8% |
| Q1 2026 | Feb 10, 2026 | $2.42vs $2.38+1.7% | $2.2Bvs $2.2B+0.9% |
| Q4 2025 | Nov 5, 2025 | $1.90vs $1.87+1.6% | $2.0Bvs $2.0B-0.5% |
| Q3 2025 | Aug 7, 2025 | $2.07vs $1.98+4.5% | $2.1Bvs $2.1B+1.0% |
Based on last 12 quarters of dataView full earnings history →
ZBH Peer Comparison
Zimmer Biomet Holdings, Inc. (ZBH) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 SNN | 12.77B | 30.08 | 20.89 | 6.34% | 6.88% | 15.06% | 0.63 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 |
Compare ZBH vs Peers
Zimmer Biomet Holdings, Inc. (ZBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZBH Income Statement
Zimmer Biomet Holdings, Inc. (ZBH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.8B | 7.93B | 7.98B | 6.13B | 6.83B | 6.94B | 7.39B | 7.68B | 8.23B | 8.41B |
Revenue Growth % | 1.76% | 1.66% | 0.62% | -23.24% | 11.42% | 1.65% | 6.55% | 3.85% | 7.2% | 9.23% |
Cost of Goods Sold | 2.13B | 2.27B | 2.25B | 1.82B | 1.96B | 2.02B | 2.08B | 2.19B | 3.16B | 2.52B |
COGS % of Revenue | 27.33% | 28.64% | 28.22% | 29.77% | 28.71% | 29.1% | 28.18% | 28.54% | 38.38% | - |
Gross Profit | 5.67B▲ 0% | 5.66B▼ 0.2% | 5.73B▲ 1.2% | 4.3B▼ 24.9% | 4.87B▲ 13.1% | 4.92B▲ 1.1% | 5.31B▲ 7.9% | 5.49B▲ 3.3% | 5.07B▼ 7.6% | 5.89B▲ 0% |
Gross Margin % | 72.67% | 71.36% | 71.78% | 70.23% | 71.29% | 70.9% | 71.82% | 71.46% | 61.62% | 70.03% |
Gross Profit Growth % | 7.26% | -0.17% | 1.21% | -24.9% | 13.1% | 1.1% | 7.93% | 3.33% | -7.57% | - |
Operating Expenses | 4.87B | 5.63B | 4.59B | 4.22B | 4.01B | 4.22B | 4.03B | 4.2B | 3.71B | 4.58B |
OpEx % of Revenue | 62.42% | 70.94% | 57.53% | 68.87% | 58.68% | 60.87% | 54.54% | 54.72% | 45.07% | - |
Selling, General & Admin | 3.1B | 3.38B | 3.34B | 2.71B | 2.84B | 2.76B | 2.84B | 2.93B | 3.25B | 3.34B |
SG&A % of Revenue | 39.79% | 42.6% | 41.89% | 44.27% | 41.65% | 39.79% | 38.39% | 38.16% | 39.5% | - |
Research & Development | 369.9M | 391.7M | 449.3M | 322.8M | 435.8M | 406M | 458.7M | 437.4M | 458.5M | 451.4M |
R&D % of Revenue | 4.74% | 4.94% | 5.63% | 5.27% | 6.38% | 5.85% | 6.2% | 5.7% | 5.57% | - |
Other Operating Expenses | 1.4B | 1.86B | 799M | 1.18B | 727.4M | 1.06B | 735.1M | 834.5M | 0 | 4M |
Operating Income | 799.3M▲ 0% | 33.8M▼ 95.8% | 1.14B▲ 3265.4% | 83.1M▼ 92.7% | 860.3M▲ 935.3% | 696.3M▼ 19.1% | 1.28B▲ 83.5% | 1.29B▲ 0.6% | 1.36B▲ 6.0% | 1.31B▲ 0% |
Operating Margin % | 10.24% | 0.43% | 14.25% | 1.36% | 12.6% | 10.03% | 17.28% | 16.74% | 16.55% | 15.61% |
Operating Income Growth % | -2.66% | -95.77% | 3265.38% | -92.69% | 935.26% | -19.06% | 83.5% | 0.63% | 5.95% | - |
EBITDA | 1.86B | 1.07B | 2.14B | 981.5M | 1.8B | 1.62B | 2.23B | 2.28B | 2.46B | 2.31B |
EBITDA Margin % | 23.86% | 13.54% | 26.85% | 16.02% | 26.34% | 23.38% | 30.15% | 29.72% | 29.84% | 27.52% |
EBITDA Growth % | 0.09% | -42.3% | 99.53% | -54.21% | 83.19% | -9.75% | 37.39% | 2.36% | 7.62% | -0.45% |
D&A (Non-Cash Add-back) | 1.06B | 1.04B | 1.01B | 898.4M | 937.7M | 926.4M | 951.7M | 996.3M | 1.09B | 1B |
EBIT | 789.9M | 18.2M | 1.13B | 106.9M | 707.4M | 568.3M | 1.27B | 1.25B | 1.12B | 1.2B |
Net Interest Income | -325.3M | -289.3M | -226.9M | -212.1M | -208.4M | -164.8M | -201.2M | -218M | -292.8M | -295.4M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 325.3M | 289.3M | 226.9M | 212.1M | 208.4M | 164.8M | 201.2M | 218M | 292.8M | 295.4M |
Other Income/Expense | -334.7M | -304.9M | -231.7M | -188.3M | -361.3M | -292.8M | -210.4M | -249.1M | -531.4M | -409.2M |
Pretax Income | 464.6M▲ 0% | -271.1M▼ 158.4% | 905.8M▲ 434.1% | -105.2M▼ 111.6% | 499M▲ 574.3% | 403.5M▼ 19.1% | 1.07B▲ 164.5% | 1.04B▼ 2.9% | 830.8M▼ 19.9% | 903.1M▲ 0% |
Pretax Margin % | 5.95% | -3.42% | 11.35% | -1.72% | 7.31% | 5.81% | 14.43% | 13.5% | 10.09% | 10.74% |
Income Tax | -1.35B | 108.2M | -225.7M | -96M | 53.5M | 112.3M | 42.2M | 131.4M | 125.7M | 142.3M |
Effective Tax Rate % | -290.31% | -39.91% | -24.92% | 91.25% | 10.72% | 27.83% | 3.95% | 12.68% | 15.13% | 15.76% |
Net Income | 1.81B▲ 0% | -379.2M▼ 120.9% | 1.13B▲ 398.4% | -138.9M▼ 112.3% | 401.6M▲ 389.1% | 231.4M▼ 42.4% | 1.02B▲ 342.5% | 903.8M▼ 11.7% | 705.2M▼ 22.0% | 761.3M▲ 0% |
Net Margin % | 23.24% | -4.78% | 14.18% | -2.27% | 5.88% | 3.33% | 13.85% | 11.77% | 8.57% | 9.05% |
Net Income Growth % | 492.94% | -120.91% | 398.42% | -112.27% | 389.13% | -42.38% | 342.52% | -11.74% | -21.97% | -16.65% |
Net Income (Continuing) | 1.81B | -379.3M | 1.13B | -9.2M | 445.5M | 291.2M | 1.03B | 905.2M | 705.1M | 760.8M |
Discontinued Operations | 0 | 0 | 0 | -128.2M | -43.4M | -58.8M | 0 | 0 | 0 | 0 |
Minority Interest | -300K | 4.8M | 4.7M | 5.2M | 5.7M | 6.7M | 7.7M | 8.1M | 0 | 0 |
EPS (Diluted) | 9.03▲ 0% | -1.86▼ 120.6% | 5.47▲ 394.1% | -0.67▼ 112.2% | 1.91▲ 385.1% | 1.10▼ 42.4% | 4.88▲ 343.6% | 4.43▼ 9.2% | 3.55▼ 19.9% | 3.89▲ 0% |
EPS Growth % | 502% | -120.6% | 394.09% | -112.25% | 385.07% | -42.41% | 343.64% | -9.22% | -19.86% | -14.82% |
EPS (Basic) | 9.11 | -1.86 | 5.52 | -0.67 | 1.93 | 1.10 | 4.91 | 4.45 | 3.56 | - |
Diluted Shares Outstanding | 203.7M | 203.5M | 206.7M | 207M | 210.4M | 210.3M | 209.7M | 203.9M | 198.7M | 195.8M |
Basic Shares Outstanding | 201.9M | 203.5M | 205.1M | 207M | 208.6M | 209.6M | 208.7M | 203.1M | 198M | 195M |
Dividend Payout Ratio | 10.67% | - | 17.38% | - | 49.83% | 86.95% | 19.62% | 21.69% | 26.99% | - |
ZBH Balance Sheet
Zimmer Biomet Holdings, Inc. (ZBH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.58B | 4.43B | 4.72B | 5.08B | 4.88B | 4.43B | 4.61B | 4.67B | 5.12B | 4.96B |
Cash & Short-Term Investments | 524.4M | 542.8M | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 525.5M | 591.9M | 424.2M |
Cash Only | 524.4M | 542.8M | 617.9M | 802.1M | 378.1M | 375.7M | 415.8M | 525.5M | 591.9M | 424.2M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.54B | 1.28B | 1.36B | 1.45B | 1.26B | 1.38B | 1.44B | 1.48B | 1.7B | 1.73B |
Days Sales Outstanding | 72.23 | 58.7 | 62.37 | 86.53 | 67.34 | 72.66 | 71.2 | 70.38 | 75.58 | 72.08 |
Inventory | 2.08B | 2.26B | 2.38B | 2.45B | 2.15B | 2.15B | 2.39B | 2.24B | 2.29B | 2.25B |
Days Inventory Outstanding | 356.26 | 362.53 | 386.45 | 490.33 | 399.93 | 388.08 | 417.79 | 372.35 | 264.13 | 342.94 |
Other Current Assets | 0 | 0 | 0 | 0 | 772.6M | 324.5M | 366.1M | 430M | 537.2M | 562.9M |
Total Non-Current Assets | 21.45B | 19.7B | 19.91B | 19.33B | 18.57B | 16.64B | 16.89B | 16.69B | 17.97B | 17.76B |
Property, Plant & Equipment | 2.04B | 2.02B | 2.08B | 2.05B | 1.84B | 1.87B | 2.06B | 2.05B | 2.21B | 2.21B |
Fixed Asset Turnover | 3.83x | 3.94x | 3.84x | 2.99x | 3.72x | 3.71x | 3.59x | 3.75x | 3.73x | 3.83x |
Goodwill | 10.67B | 9.59B | 9.6B | 9.26B | 8.92B | 8.58B | 8.82B | 8.95B | 9.95B | 9.93B |
Intangible Assets | 8.35B | 7.68B | 7.26B | 7.06B | 5.53B | 5.06B | 4.86B | 4.6B | 4.72B | 4.55B |
Long-Term Investments | 0 | 0 | 0 | 0 | 27.6M | 16.6M | 31.6M | 73.2M | 0 | 107.5M |
Other Non-Current Assets | 379.5M | 366.2M | 909.8M | 969.4M | 2.25B | 1.11B | 1.12B | 1.02B | 1.1B | 1.07B |
Total Assets | 26.01B▲ 0% | 24.13B▼ 7.3% | 24.64B▲ 2.1% | 24.42B▼ 0.9% | 23.46B▼ 3.9% | 21.07B▼ 10.2% | 21.5B▲ 2.0% | 21.37B▼ 0.6% | 23.09B▲ 8.1% | 22.72B▲ 0% |
Asset Turnover | 0.30x | 0.33x | 0.32x | 0.25x | 0.29x | 0.33x | 0.34x | 0.36x | 0.36x | 0.36x |
Asset Growth % | -2.51% | -7.25% | 2.12% | -0.9% | -3.94% | -10.19% | 2.05% | -0.61% | 8.08% | 24.89% |
Total Current Liabilities | 3.07B | 2.42B | 3.44B | 2.56B | 3.47B | 2.36B | 2.86B | 2.45B | 2.58B | 1.69B |
Accounts Payable | 330.2M | 362.6M | 400.9M | 330M | 306.5M | 354.1M | 410.6M | 194.6M | 0 | 0 |
Days Payables Outstanding | 56.51 | 58.25 | 64.96 | 66.03 | 57.07 | 64 | 71.92 | 32.42 | - | 24.04 |
Short-Term Debt | 1.23B | 525M | 1.5B | 500M | 1.61B | 544.3M | 900M | 863M | 587.1M | 1.18B |
Deferred Revenue (Current) | 0 | 0 | 0 | 145M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 319.1M | 460.4M | 321.7M | 329.8M | 640.5M | 502.8M | 326.1M | 286M | 2B | 512.5M |
Current Ratio | 1.49x | 1.83x | 1.37x | 1.99x | 1.41x | 1.88x | 1.61x | 1.91x | 1.98x | 2.94x |
Quick Ratio | 0.81x | 0.90x | 0.68x | 1.03x | 0.79x | 0.97x | 0.78x | 0.99x | 1.10x | 1.61x |
Cash Conversion Cycle | 371.97 | 362.97 | 383.86 | 510.84 | 410.2 | 396.74 | 417.07 | 410.31 | - | 390.98 |
Total Non-Current Liabilities | 11.21B | 10.43B | 8.8B | 9.66B | 7.32B | 6.68B | 6.15B | 6.44B | 7.8B | 6.3B |
Long-Term Debt | 8.92B | 8.41B | 6.72B | 7.63B | 5.46B | 5.15B | 4.87B | 5.34B | 6.93B | 6.3B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 1.1B | 999.5M | 840.1M | 790.4M | 558.5M | 474.8M | 357.6M | 352.5M | 0 | 0 |
Other Non-Current Liabilities | 1.19B | 1.02B | 1.24B | 1.24B | 1.3B | 1.05B | 925.9M | 744.1M | 870.2M | 0 |
Total Liabilities | 14.28B | 12.85B | 12.25B | 12.22B | 10.79B | 9.04B | 9.01B | 8.89B | 10.39B | 7.98B |
Total Debt | 10.14B | 8.94B | 8.22B | 8.13B | 7.07B | 5.7B | 5.77B | 6.2B | 7.52B | 7.47B |
Net Debt | 9.62B | 8.4B | 7.6B | 7.32B | 6.69B | 5.32B | 5.35B | 5.68B | 6.93B | 7.05B |
Debt / Equity | 0.86x | 0.79x | 0.66x | 0.67x | 0.56x | 0.47x | 0.46x | 0.50x | 0.59x | 0.51x |
Debt / EBITDA | 5.45x | 8.32x | 3.84x | 8.28x | 3.93x | 3.51x | 2.59x | 2.72x | 3.06x | 3.23x |
Net Debt / EBITDA | 5.17x | 7.82x | 3.55x | 7.46x | 3.72x | 3.28x | 2.40x | 2.49x | 2.82x | 3.05x |
Interest Coverage | 2.43x | 0.06x | 4.99x | 0.50x | 3.39x | 3.45x | 6.30x | 5.76x | 3.84x | 4.08x |
Total Equity | 11.74B▲ 0% | 11.28B▼ 3.9% | 12.39B▲ 9.9% | 12.2B▼ 1.6% | 12.67B▲ 3.8% | 12.03B▼ 5.0% | 12.48B▲ 3.8% | 12.48B▼ 0.0% | 12.71B▲ 1.8% | 14.74B▲ 0% |
Equity Growth % | 21.36% | -3.91% | 9.9% | -1.56% | 3.83% | -5.05% | 3.77% | -0.03% | 1.84% | 22.13% |
Book Value per Share | 57.61 | 55.41 | 59.96 | 58.93 | 60.20 | 57.19 | 59.52 | 61.19 | 63.94 | 75.27 |
Total Shareholders' Equity | 11.74B | 11.27B | 12.39B | 12.19B | 12.66B | 12.02B | 12.48B | 12.47B | 12.71B | 14.74B |
Common Stock | 3.1M | 3.1M | 3.1M | 3.1M | 3.1M | 3.1M | 3.2M | 3.2M | 0 | 0 |
Retained Earnings | 10.02B | 9.49B | 10.43B | 10.09B | 10.29B | 9.56B | 10.38B | 11.1B | 0 | 0 |
Treasury Stock | -6.72B | -6.72B | -6.72B | -6.72B | -6.72B | -6.87B | -7.56B | -8.41B | 0 | 0 |
Accumulated OCI | -83.2M | -187.4M | -241.9M | -297.8M | -231.6M | -179.3M | -191M | -262.8M | 0 | 0 |
Minority Interest | -300K | 4.8M | 4.7M | 5.2M | 5.7M | 6.7M | 7.7M | 8.1M | 0 | 0 |
ZBH Cash Flow Statement
Zimmer Biomet Holdings, Inc. (ZBH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.58B | 1.75B | 1.59B | 1.2B | 1.5B | 1.28B | 1.58B | 1.5B | 1.7B | 1.67B |
Operating CF Margin % | 20.28% | 22.03% | 19.87% | 19.66% | 21.96% | 18.51% | 21.39% | 19.53% | 20.62% | - |
Operating CF Growth % | -3.06% | 10.43% | -9.25% | -24.04% | 24.47% | -14.31% | 23.11% | -5.2% | 13.18% | 4.2% |
Net Income | 1.81B | -379.3M | 1.13B | -9.2M | 445.5M | 291.2M | 1.03B | 905.2M | 705.2M | 761.3M |
Depreciation & Amortization | 1.06B | 1.04B | 1.01B | 898.4M | 937.7M | 926.4M | 951.7M | 996.3M | 1.09B | 839.4M |
Stock-Based Compensation | 53.7M | 65.5M | 84.3M | 73.8M | 76M | 105M | 99.8M | 101M | 0 | 70.6M |
Deferred Taxes | -1.78B | 13.4M | -538.7M | 39.4M | -102.1M | -64.4M | -96.3M | -47.7M | -87.2M | -87.2M |
Other Non-Cash Items | 364.3M | 979.7M | 70.1M | 631.9M | 276.3M | 337.9M | -2.5M | 0 | 90.1M | 141.8M |
Working Capital Changes | 64.2M | 27.6M | -167.5M | -429.8M | -134.2M | -311.4M | -396.2M | -455.4M | -104.9M | -53.7M |
Change in Receivables | 161.7M | 213.6M | -93.8M | -66.2M | -40.8M | -184.7M | -51.9M | -89.7M | -127.3M | -94M |
Change in Inventory | -120.1M | -199.5M | -125.2M | -34.5M | -8.4M | -75.6M | -240.4M | 49.9M | 98.2M | 80.3M |
Change in Payables | -133.3M | 155.9M | -42M | -95.1M | 86.5M | 103M | -55.3M | -322M | 101.8M | -44.8M |
Cash from Investing | -510.8M | -416.6M | -729.3M | -613.8M | -503.6M | -529.2M | -778.9M | -888.1M | -1.98B | -2.03B |
Capital Expenditures | -156M | -162.7M | -207.1M | -111.9M | -143.6M | -187.9M | -291.1M | -203.8M | -276.9M | 110.7M |
CapEx % of Revenue | 2% | 2.05% | 2.59% | 1.83% | 2.1% | 2.71% | 3.94% | 2.65% | 3.36% | 1.32% |
Acquisitions | -4M | -15.3M | -37.1M | -227.1M | 0 | -99.8M | -134.9M | -276.3M | -1.39B | -1.39B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -13.8M | -31.5M | -217.3M | -69.3M | -88.3M | -72.6M | -74.6M | -189.8M | -4.7M | -509.3M |
Cash from Financing | -1.21B | -1.3B | -779.9M | -421.8M | -1.31B | -843.8M | -763.5M | -484.5M | 326M | -618.6M |
Debt Issued (Net) | -1.25B | -1.15B | -716.1M | -252.9M | -1.05B | -1.06B | 54.6M | 536.3M | 1.01B | 138.6M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 122.5M | -126.4M | -692.2M | -868M | -447.3M | -256.3M |
Dividends Paid | -193.6M | -195.2M | -196.7M | -198.5M | -200.1M | -201.2M | -200.9M | -196M | -190.3M | -189.4M |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -126.4M | -692.2M | -868M | -487M | -270.3M |
Other Financing | 231.3M | 47.4M | 132.9M | 29.6M | -173.4M | 544.5M | 75M | 43.2M | -42.8M | -311.5M |
Net Change in Cash | -109.7M▲ 0% | 18.4M▲ 116.8% | 75.1M▲ 308.2% | 184.2M▲ 145.3% | -323.6M▼ 275.7% | -102.8M▲ 68.2% | 40.1M▲ 139.0% | 109.7M▲ 173.6% | 66.4M▼ 39.5% | -960.3M▲ 0% |
Free Cash Flow | 1.43B▲ 0% | 1.58B▲ 11.1% | 1.18B▼ 25.5% | 1.09B▼ 7.5% | 1.35B▲ 23.3% | 1.07B▼ 20.8% | 1.19B▲ 11.2% | 1.14B▼ 3.7% | 1.47B▲ 28.9% | 1.84B▲ 0% |
FCF Margin % | 18.28% | 19.98% | 14.8% | 17.83% | 19.73% | 15.38% | 16.05% | 14.88% | 17.89% | 21.83% |
FCF Growth % | -1.46% | 11.11% | -25.47% | -7.49% | 23.3% | -20.79% | 11.25% | -3.75% | 28.87% | 36.08% |
FCF per Share | 7.00 | 7.79 | 5.71 | 5.28 | 6.40 | 5.07 | 5.66 | 5.60 | 7.41 | 9.37 |
FCF Conversion (FCF/Net Income) | 0.87x | -4.61x | 1.40x | -8.67x | 3.73x | 5.55x | 1.54x | 1.66x | 2.41x | 2.41x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZBH Key Ratios
Zimmer Biomet Holdings, Inc. (ZBH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 16.95% | -3.3% | 9.56% | -1.13% | 3.23% | 1.87% | 8.36% | 7.24% | 5.6% | 5.77% |
Return on Invested Capital (ROIC) | 2.88% | 0.12% | 4.3% | 0.32% | 3.32% | 2.85% | 5.45% | 5.36% | 5.41% | 4.89% |
Gross Margin | 72.67% | 71.36% | 71.78% | 70.23% | 71.29% | 70.9% | 71.82% | 71.46% | 61.62% | 70.03% |
Net Margin | 23.24% | -4.78% | 14.18% | -2.27% | 5.88% | 3.33% | 13.85% | 11.77% | 8.57% | 9.05% |
Debt / Equity | 0.86x | 0.79x | 0.66x | 0.67x | 0.56x | 0.47x | 0.46x | 0.50x | 0.59x | 0.51x |
Interest Coverage | 2.43x | 0.06x | 4.99x | 0.50x | 3.39x | 3.45x | 6.30x | 5.76x | 3.84x | 4.08x |
FCF Conversion | 0.87x | -4.61x | 1.40x | -8.67x | 3.73x | 5.55x | 1.54x | 1.66x | 2.41x | 2.41x |
Revenue Growth | 1.76% | 1.66% | 0.62% | -23.24% | 11.42% | 1.65% | 6.55% | 3.85% | 7.2% | 9.23% |
Related:ZBH Dividend History·ZBH Revenue History·ZBH Price History·ZBH P/E History·ZBH Financial Ratios·ZBH Institutional Holders
ZBH SEC Filings & Documents
Zimmer Biomet Holdings, Inc. (ZBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZBH Frequently Asked Questions
Zimmer Biomet Holdings, Inc. (ZBH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.41B in revenue for fiscal year 2025. This represents a 796% increase from $939.0M in 1999.
Zimmer Biomet Holdings, Inc. (ZBH) grew revenue by 7.2% over the past year. This is steady growth.
Yes, Zimmer Biomet Holdings, Inc. (ZBH) is profitable, generating $761.3M in net income for fiscal year 2025 (8.6% net margin).
Dividend & Returns
Yes, Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend with a yield of 1.09%. This makes it attractive for income-focused investors.
Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity (ROE) of 5.6%. This is below average, suggesting room for improvement.
Zimmer Biomet Holdings, Inc. (ZBH) generated $1.84B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.